NasdaqGS:CRNXPharmaceuticals
Crinetics Pharmaceuticals (CRNX) Agreed To A $10 Billion All Cash Sale To Vertex
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals (NasdaqGS:CRNX) in an all cash deal valued at about US$10b.
The boards of both companies approved the transaction unanimously.
The deal is expected to close in Q3 2026, subject to regulatory and Crinetics shareholder approvals.
Crinetics Pharmaceuticals focuses on endocrine diseases, an area where larger drug makers have been looking to expand their presence. Vertex is set to add Crinetics' pipeline and clinical expertise to...